FR 173657

structure given in first source

Also Known As:

(E)-3-((6-acetamido-3-pyridyl)-N-(N-(2,4-dichloro-3-((2-methyl-8-quinolinyl)oxymethyl)phenyl)-N-methyl) aminocarbonyl methyl)acrylamide; FK3657; FR-173657; FR173657

Networked: 30 relevant articles (1 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - FR 173657: 30

Experts

1.	Matsumoto, Koshi: 4 articles (01/2005 - 09/2002)
2.	Morishita, Yasuo: 4 articles (01/2005 - 09/2002)
3.	Takeyoshi, Izumi: 4 articles (01/2005 - 09/2002)
4.	Totsuka, Osamu: 4 articles (01/2005 - 09/2002)
5.	Bader, Michael: 3 articles (01/2020 - 01/2009)
6.	Cabrini, Daniela Almeida: 3 articles (01/2020 - 01/2009)
7.	Otuki, Michel Fleith: 3 articles (01/2020 - 01/2009)
8.	Pesquero, João Bosco: 3 articles (01/2020 - 01/2009)
9.	Hayashi, Izumi: 3 articles (03/2009 - 03/2002)
10.	Majima, Masataka: 3 articles (03/2009 - 03/2002)

Related Diseases

1.	Reperfusion Injury 01/01/2005 - "Bradykinin B2 receptor antagonist FR173657 ameliorates small bowel ischemia-reperfusion injury in dogs." 11/01/2004 - "This study evaluated the effects of a bradykinin B2 receptor antagonist, FR173657 (FR), on ischemia-reperfusion injury during liver resection in dogs. " 09/01/2002 - "Effects of a bradykinin B(2) receptor antagonist, FR173657, on pulmonary ischemia-reperfusion injury in dogs."
2.	Ischemia 01/01/2005 - "The aim of this study was to evaluate the effect of a bradykinin B2 receptor antagonist, FR173657 (FR), on intestinal ischemia-reperfusion (I/R) injury. " 09/01/2002 - "This study investigated the effects of a bradykinin B(2) receptor antagonist, FR173657 (FR), on pulmonary ischemia-reperfusion (I/R) injury. " 05/01/2004 - "This study investigated the effects of a bradykinin B(2) receptor antagonist, FR173657 (FR), on ischemia-reperfusion (I/R) injury in a canine lung transplantation model. "
3.	Tics (Tic) 01/01/2003 - "The B(2) receptor antagonists FR 173657 ((E)-3-(6-acetamido-3-pyridyl)-N [N-2-4-dichloro-3-[(2-methyl-8-quinolinyl) oxymethyl] phenyl]-N-methylamino-carbonyl-ethyl] acrylamide) and Hoe 140 (D-Arg(0)-[Hyp(3), Thi(5), D-Tic(7), Oic(8)]-bradykinin produced a graded shift to the right associated with marked inhibition of the bradykinin-induced contraction. " 01/01/2002 - "As the specific peptide antagonist D-Arg-[Hyp(3),Thi(5),D-Tic(7),Oic(8)]-bradykinin (HOE140), (E)-3-(6-acetamido-3-pyridil)-N-[-N-[2,4-dichloro-3-[(2-methyl-8-quinolinyl)oxymethyl]phenyl]-N-methylaminocarbonylmethyl]acrylamide (FR173657) and 1-[[3-[2,4-dimethylquinolin-8-yl)oxymethyl] - 2,4 - dichloro - phenyl]sulfonyl] - 2(S) - [[4-[4-(aminoiminomethyl)-phenylcarbonyl]piperazin-1-yl]carbonyl]pyrrolidine (LF16-0335C) exhibited a high affinity for this receptor with K(i) values of 7.34+/-2.45 nM and 8.54+/-1.55 nM respectively. " 12/01/2000 - "This study examined the mitogenic effects of bradykinin (BK, Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg), the peptide bradykinin B(2) receptor antagonist Hoe 140 (D-Arg(0)[Hyp(3)-Thi(6)-D-Tic(7)-Oic(8)]BK, and the orally active, nonpeptide B(2) receptor antagonist FR 173657 ((E)-3-(6-acetamido-3-pyridyl)-N-[N-2-4-dichloro-3-[(2-methyl-8-quino linyl) oxymethyl]phenyl]-N-methylaminocarbonyl-methyl]acrylamide) in three different human tumour cell lines: the small cell lung carcinoma (SCLC) cell line H-69, the breast carcinoma cell line EFM-192A, and the colon carcinoma cell line SW-480. "
4.	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 12/01/2000 - "This study examined the mitogenic effects of bradykinin (BK, Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg), the peptide bradykinin B(2) receptor antagonist Hoe 140 (D-Arg(0)[Hyp(3)-Thi(6)-D-Tic(7)-Oic(8)]BK, and the orally active, nonpeptide B(2) receptor antagonist FR 173657 ((E)-3-(6-acetamido-3-pyridyl)-N-[N-2-4-dichloro-3-[(2-methyl-8-quino linyl) oxymethyl]phenyl]-N-methylaminocarbonyl-methyl]acrylamide) in three different human tumour cell lines: the small cell lung carcinoma (SCLC) cell line H-69, the breast carcinoma cell line EFM-192A, and the colon carcinoma cell line SW-480. "
5.	Carcinoma (Carcinomatosis) 12/01/2000 - "This study examined the mitogenic effects of bradykinin (BK, Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg), the peptide bradykinin B(2) receptor antagonist Hoe 140 (D-Arg(0)[Hyp(3)-Thi(6)-D-Tic(7)-Oic(8)]BK, and the orally active, nonpeptide B(2) receptor antagonist FR 173657 ((E)-3-(6-acetamido-3-pyridyl)-N-[N-2-4-dichloro-3-[(2-methyl-8-quino linyl) oxymethyl]phenyl]-N-methylaminocarbonyl-methyl]acrylamide) in three different human tumour cell lines: the small cell lung carcinoma (SCLC) cell line H-69, the breast carcinoma cell line EFM-192A, and the colon carcinoma cell line SW-480. "

Related Drugs and Biologics

1.	Bradykinin B2 Receptor
2.	Bradykinin
3.	2,5-dichloro-4-bromophenol (B 2)
4.	icatibant
5.	Peptides (Polypeptides)
6.	Kinins
7.	2- ((3- (1,3- benzodioxol- 5- yl)- 3- (((6- methoxy- 2- naphthyl)sulfonyl)amino)propanoyl)amino)- 3- (4- ((2,6- dimethylpiperidinyl)methyl)phenyl)- N- isopropyl- N- methylpropanamide
8.	Enalapril
9.	Carrageenan
10.	Antigens

Related Therapies and Procedures

1.	Lung Transplantation
2.	Operative Surgical Procedures
3.	Oral Administration